astrazeneca glp 1 drug launches GLP-1 combo to treat obesity co-morbidities AstraZeneca signs $18.5 billion weight-loss-drug
Description
71 Furthermore, GLP-1RA has been investigated for its potential to reduce the risk of cardiovascular events in patients with or without diabetes
Fortunately, the agent itself has an independent effect on curbing alcohol intake and cravings by affecting brain pathways related to reward and addiction
This mechanism of promoter binding leads to increased DPP-4 transcription [33]
It turns out that insulin secretion is enhanced by a multi-process mechanism [1]
Once the treatment is stopped, the effects are reversed fairly quickly
An uncommon side effect the risk is less than 2% is gallstones, which are small, rock-like deposits of hardened digestive fluid
